Skip to content

    Star Health Insu

    STARHEALTHWeak
    Financial Services·30 Apr 2025
    Management Summary

    Star Health closed FY25 with strong premium growth but faced significant pressure on profitability due to elevated claim ratios. The company is aggressively recalibrating its group business and implementing cohort-based pricing to manage loss ratios. Despite a 'bad year' for claims, management remains committed to a long-term vision of tripling profits by FY28 through digital transformation and agency expansion.

    Highlights

    8

    • FY25 PAT stood at ₹787 crores, a 28.6% decline from ₹1,103 crores in FY24

    • Overall Gross Written Premium (GWP) grew by 15% YoY, with fresh GWP growing by 22%

    • Claim ratio deteriorated to 70.7% in FY25 compared to 66.5% in FY24

    • Combined ratio rose to 101.1% from 97.3% YoY, reflecting elevated claim frequency and severity

    • Retail health segment maintains a dominant 33% market share, nearly 3x the nearest competitor

    • Solvency ratio remains robust at 2.21x, well above the regulatory requirement of 1.5x

    • Investment income grew to ₹1,260 crores with a yield of 7.7%

    • Management set an ambitious FY28 target to double the top line and triple the profit on an IFRS basis

    Concerns

    2

    • Elevated Claim Frequency and Severity

    • Medical Inflation Discrepancy

    What Changed1

    vs Q1 FY26

    Tone shiftGood → Weak

    Key financials

    Single quarter

    06 metrics
    1. 01Gross Written Premium15%+15%YoY
    2. 02PAT₹787 Cr-28.6%YoY
    3. 03Claim Ratio70.7%
    4. 04Combined Ratio101.1%
    5. 05Investment Income₹1,260 Cr+7.6%YoY

    Segment breakdown

    Loss RatioPremium Contribution (Q4)
    Retail Health68%95%
    Group Business89.8%5%
    Agency Channel——
    Heatmap· 2 shared metrics

    Guidance & targets

    4
    CategoryTargetPriority
    Profitability
    IFRS Profit
    3x current
    		Medium
    Revenue
    Top Line
    2x current
    		Medium
    Headcount
    Agent Network
    1,000,000
    		High
    Margin
    FHO Loss Ratio Improvement
    2-3%
    		Medium

    Risks & concerns

    6
    RiskSeverity

    Elevated Claim Frequency and Severity

    Driven by increased surgical interventions (cancer, gynae, obstetrics) and a shift from secondary to tertiary care. — Both acknowledged

    high

    Medical Inflation Discrepancy

    Management cites 15% inflation while analysts claim industry peers report mid-single digits; this gap creates uncertainty in pricing adequacy. — Analyst deflected

    high

    Adverse Selection from Price Hikes

    Aggressive price hikes in FHO products led to 5-6% customer drop-offs, primarily among non-claiming 'good' risks. — Both acknowledged

    medium

    Areas of Evasion(3)

    • Specific loss ratio split for newer vs older cohorts (deferred to 'offline')
    • Justification for the 15% medical inflation figure vs industry data
    • Direct impact of price hikes on current loss ratios

    Q&A highlights

    3

    “I find that this is a misconception I don't think anybody in the industry is close to 15%... I can't understand this misconception around why you believe the industry is at 15% and you are doing any better?”

    Analysts challenged management's claim of 15% medical inflation, suggesting management might be using high inflation figures to mask internal underwriting or claim management failures.

    asked by Krishnan ASV, HDFC Securities

    1 min read5 chapters

    Detailed Narrative

    01

    Loss Ratio Pressures and Claim Dynamics

    The overall claim ratio rose to 70.7% in FY25, driven by a 7% increase in claim frequency and higher severity in surgical interventions. Management noted a shift from secondary to tertiary care and increased screenings for cancer as primary drivers. Despite taking price corrections in 60% of the portfolio, the benefits have been offset by these structural shifts in healthcare utilization.

    02

    Strategic Recalibration of Group Business

    Star Health is consciously reducing its exposure to the group insurance segment, which saw loss ratios spike to 89.8% from 77.3% YoY. In Q4 FY25, the group segment's contribution to total premium was slashed to just 5%. Management is now highly selective, focusing only on profitable MSME cohorts to protect the overall combined ratio.

    03

    Distribution Channel Evolution (ABCD)

    The Agency channel remains the bedrock, contributing 82% of GWP with a plan to reach 1 million agents in three years. The Digital segment showed the most aggressive growth, with fresh business up 71% YoY. Meanwhile, Bancassurance growth has moderated as banks prioritize regulatory compliance over insurance distribution following new '1 by n' guidelines.

    04

    Pricing Strategy and Cohort-Based Incentives

    To combat adverse selection, the company is moving toward 'nuanced' price corrections. This includes offering discounts to customers with good claim histories to improve persistency. Management expects the latest price hikes in the Family Health Optima (FHO) product, implemented in January, to yield a 2-3% improvement in loss ratios over the next 12 months.

    05

    Ambitious FY28 Financial Targets

    Despite the current profitability dip, management reiterated its 'medium-term vision' for FY28. The target is to double the top-line premium and triple the net profit on an IFRS basis. This growth is expected to be fueled by digital-first execution, AI-led pre-authorizations, and deeper penetration into semi-urban and rural markets.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.